164 related articles for article (PubMed ID: 9412619)
21. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
[TBL] [Abstract][Full Text] [Related]
23. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
Janzic A; Kos M
Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
[TBL] [Abstract][Full Text] [Related]
27. Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation.
Djukic M; Braun LM; Unkel S; Jacobshagen C; Nau R
Drugs Aging; 2018 Sep; 35(9):859-869. PubMed ID: 30066299
[TBL] [Abstract][Full Text] [Related]
28. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
29. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage.
Chao TF; Liu CJ; Liao JN; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chen TJ; Lip GY; Chen SA
Circulation; 2016 Apr; 133(16):1540-7. PubMed ID: 26969761
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin for Preventing Further Cerebral Microbleeds in Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation and At Least One Microbleed: CMB-NOW Multisite Pilot Trial.
Yokoyama M; Mizuma A; Terao T; Tanaka F; Nishiyama K; Hasegawa Y; Nagata E; Nogawa S; Kobayashi H; Yanagimachi N; Okazaki T; Kitagawa K; Takizawa S;
J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):1918-1925. PubMed ID: 31005561
[TBL] [Abstract][Full Text] [Related]
31. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
32. Effect of long-term oral anticoagulant therapy on bone mineral density and bone turnover markers: a prospective 12 month study.
Stenova E; Steno B; Killinger Z; Baqi L; Payer J
Bratisl Lek Listy; 2011; 112(2):71-6. PubMed ID: 21456505
[TBL] [Abstract][Full Text] [Related]
33. Protocol for Cerebral Microbleeds during the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial.
Takizawa S; Tanaka F; Nishiyama K; Hasegawa Y; Nagata E; Mizuma A; Yutani S; Nakayama T; Kobayashi H; Yanagimachi N; Okazaki T; Kitagawa K;
J Stroke Cerebrovasc Dis; 2015 Sep; 24(9):2143-8. PubMed ID: 26153510
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
35. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.
Himmler S; Müller M; Ostwald D; Seddik A; Basic E; Hradetzky E
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):223-230. PubMed ID: 30295561
[TBL] [Abstract][Full Text] [Related]
36. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GYH; Larsen TB
Stroke; 2019 Apr; 50(4):939-946. PubMed ID: 30869568
[TBL] [Abstract][Full Text] [Related]
37. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
[TBL] [Abstract][Full Text] [Related]
38. Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin.
Nomura E; Ohshita T; Imamura E; Wakabayashi S; Kajikawa H; Hosomi N; Matsumoto M
Circ J; 2015; 79(4):862-6. PubMed ID: 25736910
[TBL] [Abstract][Full Text] [Related]
39. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with ischemic stroke on therapeutic anticoagulation in patients with nonvalvular atrial fibrillation.
Kim YD; Lee KY; Nam HS; Han SW; Lee JY; Cho HJ; Kim GS; Kim SH; Cha MJ; Ahn SH; Oh SH; Lee KO; Jung YH; Choi HY; Han SD; Lee HS; Nam CM; Kim EH; Lee KJ; Song D; Park HN; Heo JH
Yonsei Med J; 2015 Mar; 56(2):410-7. PubMed ID: 25683989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
